C4 Therapeutics Inc is trading at $3.95 (5.3% down) as the stock pulls back following a sharp multi-day rally and recent analyst upgrades that had previously driven shares higher.
- The decline appears to be driven by profit-taking in the volatile, high-beta name following its recent period of outperformance.
- Broader market pressure is weighing on growth assets, with major U.S. indices dropping more than 1% in a risk-off trading session on June 5.
- There are no new company-specific headlines to account for the move, suggesting the price action is technical and sentiment-driven.